Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results.

Chi BH, Kim SC.

Korean J Urol. 2011 Sep;52(9):632-6. doi: 10.4111/kju.2011.52.9.632. Epub 2011 Sep 28.

2.

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.

O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K.

BJU Int. 2003 Aug;92(3):262-6.

3.

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.

Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET.

Urology. 2004 Apr;63(4):709-15.

PMID:
15072886
4.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.

Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.

PMID:
21764428
5.

Serial Changes in Sexual Function Following Holmium Laser Enucleation of the Prostate: A Short-term Follow-up Study.

Jeong MS, Ha SB, Lee CJ, Cho MC, Kim SW, Paick JS.

Korean J Urol. 2012 Feb;53(2):104-8. doi: 10.4111/kju.2012.53.2.104. Epub 2012 Feb 20.

6.
7.

Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment.

Kim TB, Oh JK, Kim KH, Jung H, Yoon SJ, Lee MS, Kim SW.

BJU Int. 2012 Dec;110(11 Pt C):E857-63. doi: 10.1111/j.1464-410X.2012.11343.x. Epub 2012 Jul 3.

8.

Clinical effects of discontinuing 5-alpha reductase inhibitor in patients with benign prostatic hyperplasia.

Kim W, Jung JH, Kang TW, Song JM, Chung HC.

Korean J Urol. 2014 Jan;55(1):52-6. doi: 10.4111/kju.2014.55.1.52. Epub 2014 Jan 15.

9.

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F; CombAT Study Group.

Eur Urol. 2009 Feb;55(2):461-71. doi: 10.1016/j.eururo.2008.10.037. Epub 2008 Nov 6.

PMID:
19013011
10.
11.

The different reduction rate of prostate-specific antigen in dutasteride and finasteride.

Choi YH, Cho SY, Cho IR.

Korean J Urol. 2010 Oct;51(10):704-8. doi: 10.4111/kju.2010.51.10.704. Epub 2010 Oct 21.

12.

Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study.

Arai Y, Aoki Y, Okubo K, Maeda H, Terada N, Matsuta Y, Maekawa S, Ogura K.

J Urol. 2000 Oct;164(4):1206-11.

PMID:
10992367
13.

Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.

Gittelman M, Ramsdell J, Young J, McNicholas T.

J Urol. 2006 Sep;176(3):1045-50; discussion 1050.

PMID:
16890688
14.

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.

Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C; ARIA3001, ARIA3002 and ARIB3003 Study Investigators.

Eur Urol. 2004 Oct;46(4):488-94; discussion 495.

PMID:
15363566
15.

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS.

BJU Int. 2011 Aug;108(3):388-94. doi: 10.1111/j.1464-410X.2011.10195.x. Epub 2011 Jun 1.

16.

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F; CombAT Study Group.

J Urol. 2008 Feb;179(2):616-21; discussion 621. Epub 2007 Dec 21. Erratum in: J Urol. 2008 Sep;180(3):1191.

PMID:
18082216
17.
18.
20.

Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.

Marihart S, Harik M, Djavan B.

Rev Urol. 2005 Fall;7(4):203-10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk